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ABSTRACT
Background The Wales National Exercise Referral
Scheme (NERS) is a 16-week programme including
motivational interviewing, goal setting and relapse
prevention.
Method A pragmatic randomised controlled trial with
nested economic evaluation of 2160 inactive participants
with coronary heart disease risk (CHD, 1559, 72%),
mild to moderate depression, anxiety or stress (79, 4%)
or both (522, 24%) randomised to receive (1) NERS or
(2) normal care and brief written information.
Outcome measures at 12 months included the 7-day
physical activity recall, the hospital anxiety and
depression scale.
Results Ordinal regression identified increased physical
activity among those randomised to NERS compared
with those receiving normal care in all participants (OR
1.19, 95% CI 0.99 to 1.43), and among those referred for
CHD only (OR 1.29, 95% CI 1.04 to 1.60). For those
referred for mental health reason alone, or in
combination with CHD, there were significantly lower
levels of anxiety (OR 1.56, 95% CI 2.75 to 0.38)
and depression (OR 1.39, 95% CI 2.60 to 0.18),
but no effect on physical activity. The base-case
incremental cost-effectiveness ratio was £12 111 per
quality adjusted life year, falling to £9741 if participants
were to contribute £2 per session.
Conclusions NERS was effective in increasing physical
activity among those referred for CHD risk only. Among
mental health referrals, NERS did not influence physical
activity but was associated with reduced anxiety and
depression. Effects were dependent on adherence. NERS
is likely to be cost effective with respect to prevailing
payer thresholds.
Trial registration Current Controlled Trials
ISRCTN47680448.
INTRODUCTION
It is widely recognised that regular physical activity
is beneﬁcial to both physical and mental health1 It
is associated with reduced risk from chronic
diseases, including coronary heart disease (CHD)2
and has been shown to be positively linked to
mental health,3 including depression.4 Exercise
referral schemes (ERS) can target speciﬁc patient or
population subgroups with such conditions by
providing contact with qualiﬁed exercise profes-
sionals (EP) and access to tailored programmes
promoting physical activity.
Despite the rapid growth of ERS in the UK, the
evidence base for their effectiveness and cost
effectiveness is equivocal. The latest systematic
review evidence prior to this study identiﬁed six
randomised controlled trials from the UK,5 where
a modest but statistically signiﬁcant improvement
in activity with a combined RR of 1.2 (95% CI 1.06
to 1.35) was partly explained by poor rates of
uptake and adherence, and a lack of intervention
relapse-prevention strategies. Overall, results were
consistent with previous reviews in that ERS
increased physical activity in individuals who were
already slightly active,6 7 increases were not main-
tained long-term7 and scheme attendance was
poor.8 International cost-effectiveness evidence was
also equivocal,5 9 with a pre-study review10 iden-
tifying nine studies varying from €348 to €86 877
(£304 to £75 982) per quality adjusted life year
(QALY) depending on scheme intensity.
In light of this, and the development of variable
localised ERS throughout the UK, rigorous evidence
is needed to distinguish scheme content that facil-
itates uptake and adherence and promotes long-
term improvements in activity.11 This paper reports
an independent evaluation of the Welsh Govern-
ment’s National Exercise Referral Scheme (NERS)
operating in 12 local health board (LHB) areas in
Wales, UK, assessing its effectiveness and cost
effectiveness in increasing physical activity and
reducing anxiety and depression among patients
referred for CHD risk and/or anxiety, depression
and stress.
METHODS
Study design
A pragmatic randomised controlled trial, with
nested process and economic evaluations (for full
details, see published study protocol12).
Recruitment of participants
Those eligible for the scheme were sedentary and
had at least one medical condition (table 1).
Patients were identiﬁed opportunistically by clini-
cians in normal practice and were provided with
basic trial information by the clinician who
completed a referral form forwarded to the evalu-
ation team. Those referred for reasons other than
CHD and mental health could access the scheme
outside of the trial, while those referred with CHD
risk factors and/or mild to moderate anxiety,
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depression or stress were eligible for the trial and were sent full
informed consent materials and a brief baseline questionnaire,
with non-responders sent a repeat mailing 2 weeks later. The
postal questionnaire requested demographic details, post code of
residence and the general practice physical activity questionnaire
(GPPAQ).13 Eligible patients declining to participate in the trial
entered a 12-month waiting list.
Randomisation
Each participant who consented and returned a completed
baseline questionnaire was assigned a unique ID and entered
sequentially into the study database. These were randomly
assigned to the intervention ERS or control trial arm using
a random number generator, with gender and LHB as stratiﬁ-
cation variables. Randomisation of forwarded referral forms
occurred every 2 weeks, with treatment allocation blind and
remote from participants and practitioners.
Intervention
The intervention followed a standardised protocol and was
delivered at leisure centres by exercise professionals (EP) in each
LHB14 15 (box 1). The content, duration and intensity of the
scheme were designed to promote adherence and long-term
improvements in activity. Consultations were based on moti-
vational interview16 principles which facilitated patient-centred
achievable goals, and included relapse-prevention strategies at 4
and 16 weeks to review goals and encourage attendance.14 The
primary goal was for participants to achieve 30 min of moderate
physical activity on at least 5 days per week. EPs delivering the
programme were not directly aware of whether or not a client
was a trial participant but could potentially identify this on the
basis of the reason for referral. Blinding of participants was not
feasible. The control group received usual care and a leaﬂet
highlighting the beneﬁts of exercise, and were given the
addresses of local facilities.
Sample size
Sample size was determined to detect a difference in total
minutes of weekly activity at 12 months, with 1052 participants
in each group providing 90% power to detect an effect size of 0.15
with no loss to follow-up and, more realistically, 87% and 84%
power to detect an effect size of 0.15 if 20% and 25%, respectively,
of randomised participants who were lost to follow-up.
Table 1 Scheme inclusion/exclusion criteria used by clinicians in normal practice and trial eligibility
Scheme inclusion criteria Scheme exclusion criteria Trial eligibility
The patient must be sedentary (defined as not moderately
active for $3 times per week or deconditioned through age
or inactivity), and have at least one of the following medical
conditions:
< CHD risk factors
– Raised blood pressure more than 140/90 (either) but
<180/100 (either)
– Weight management
– BMI >28
– Controlled diabetes
– Impaired glucose tolerance
– High cholesterol >5.0
– Family history of heart disease or diabetes
– Referral from Cardiac Rehabilitation Schemes (only
from phase IV)
< Mental health
– Mild anxiety, depression or stress
< Musculoskeletal
– At risk of osteoporosis
– Arthritis (mild)
– Poor mobility
– Musculoskeletal pain including back pain
< Respiratory/pulmonary
– COPD
– Mild/moderate well controlled
– (asthma, bronchitis, emphysema)
< Neurological conditions
– Multiple sclerosis
< Other
– Smoker
– Chronic fatigue
< Aged #16 years
< Unstable angina
< Blood pressure 180/100 (in either) or
above and/or uncontrolled or poorly
controlled hypertension
< Cardiomyopathy
< Uncontrolled tachycardia
< Cardiac arrhythmia
< Valvular heart disease
< Congenital heart disease
< Unexplained dizzy spells
< Excessive or unexplained breathlessness
on exertion
< Uncontrolled or poorly controlled diabetes
< Uncontrolled or poorly controlled epilepsy
< History of falls or dizzy spells in the last
12 months
< Uncontrolled or poorly controlled asthma
(severe COPD)
< First 12 weeks of pregnancy
< Awaiting medical investigation
< Aneurysms
< History of cerebro-vascular disease
< Unstable/newly diagnosed angina (within
6 months)
< Established coronary heart disease (including
myocardial infarction)
< Any other uncontrolled condition
The patient must be sedentary and have at
least one of the following condition:
< CHD risk factors
– raised blood pressure more than
140/90 (either) but <180/100 (either)
– weight management
– BMI >28
– controlled diabetes
– impaired glucose tolerance
– high cholesterol >5.0
– family history of heart disease or diabetes
– referral from Cardiac Rehabilitation
Schemes (only from phase IV), and or
< Mental health
– mild anxiety, depression or stress
BMI, body mass index; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease.
Box 1 Delivery of the Welsh National Exercise Referral
Scheme (NERS)
16-week tailored programme of exercise supervised by
a qualified exercise professional
< Initial consultation with exercise professional on entry:
lifestyle questionnaire, health check (resting heart rate,
blood pressure, body mass index and waist circumference),
introduction to leisure centre facilities, motivational interview
and goal setting.
< Access to one-to-one exercise instruction and/or group
exercise classes. Discounted rate for exercise activities, £1
per session.
< Four-week telephone contact with exercise professionald
review of goals, motivational interview, relapse prevention.
< Sixteen-week consultation with exercise professionald
review of goals, motivational interview, health check, lifestyle
questionnaire, service evaluation questionnaire14 and advice
on continuing with exercise after the programme.
Post-16-week activities
< 8-months telephone contact by exercise professional to ask
about their exercise behaviour and relapse prevention.
< 12-months review including repeat of health check carried out
at entry and Chester fitness step test.15
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Outcome measures
The primary outcome was total minutes of weekly physical
activity at 12-month follow-up, assessed using the 7-day phys-
ical activity recall (7D-PAR)17 administered by telephone18 with
interviewees blind to group allocation. For those telephone
respondents unwilling to complete the 7D-PAR, the briefer
GPPAQ measure was administered where possible.
A postal questionnaire was also sent to all study participants
at 6 and 12 months, with non-responders sent a repeat mailing 2
weeks later. At 6 and 12 months, participants completed an
adapted Client Service Receipt Inventory,19 the health-related
quality of life measure EQ-5D20 and willingness-to-pay ques-
tion.21 The outcome measure for the economic analysis was the
QALY derived using the EQ-5D, a generic preference-based
instrument for measuring health-related quality of life.20 The
Client Service Receipt Inventory questionnaire19 asked partici-
pants to recall their contacts with NHS primary care (including
prescribing) and secondary care services over the preceding
6 months (baseline) and at 6 and 12 months after baseline. The
questionnaire at 12 months also included a question asking
participants how much (in UK pounds) they were, in theory,
willing to pay for exercise sessions through NERS.21 At
12 months, the questionnaire included the Baecke Questionnaire
of Habitual Physical Activity (Baecke)22 and the Hospital
Anxiety and Depression Scale (HADS) (1983)23 to assess
depression and anxiety as secondary outcomes.
Analysis
As the primary outcome (7-D PAR) has a highly skewed and
bimodal distribution, it was recoded according to approximate
quintiles as a ﬁve-level ordinal variable, and proportional odds
ordinal regression models were used with the stratiﬁcation vari-
ables (gender, LHB area, age group (16e44, 45e59, 60+)) and
baseline activity level (GPPAQ) as covariates. Secondary analysis
excluded baseline activity level as a covariate. Analyses were
repeated with imputed values for those who did not complete the
7-D PAR, but who did complete either the Baecke or GPPAQ at 12
months, using stochastic imputation based on their Baecke or
GPPAQ measures. Subgroup analyses for gender, age group
(16e44, 45e59, 60+), referral reason (mental health only, CHD
only, or combination of CHD and mental health), and tertile
of Welsh Index of Multiple Deprivation obtained for the lower-
layer super-output area of the participants’ postcode of resi-
dence,24 was assessed by including the main effect and interaction
in separate models. We used the same approach with linear
regression to explore our secondary outcome measures (HADS)
for mental health referrals, or those referred for mental health/
CHD combined. The analyses of HADS among all participants are
secondary to this analysis. Analyses were conducted on an
intention-to-treat basis with the statistician unaware of how the
treatment group variable was coded. For each outcome per
protocol, analyses to identify whether outcomes vary in terms of
adherence to the programme replaced the binary intervention
variable with a three-level programme attendance variable; full
attendance (for 16 weeks), partial attendance (1e16 weeks), and
no exposure to programme (control group or non-attender).
Economic evaluation
Costs and beneﬁts of NERS were estimated from a public sector
perspective and were not discounted, as follow-up was for
1 year. A primary cost-utility analysis was conducted using the
base-case intervention cost per participant (£385; n¼3530). As
Figure 1 Flow diagram of the study.
EQ5D, EuroQold5 Dimensions; HADS,
Hospital Anxiety and Depression Scale;
NERS, National Exercise Referral
Scheme; 7-D PAR, 7-day physical
activity recall.
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EQ-5D was not included in the minimal data collection at
baseline in this trial, conservatively, 6-month EQ-5D values were
used as a baseline estimate to generate an incremental cost-
effectiveness ratio (ICER) at 12 months and cost effectiveness
acceptability curve to compare with the National Institute of
Health and Clinical Excellence (NICE) cost per QALY threshold
of £20 000e£30 000.25 National unit costs were applied to
service use frequency data to estimate total costs of service use
for patients,26e28 and cost per QALY estimates were calculated
using utility weights from EQ-5D.29 When EQ-5D data were
missing for 1 or 2 domains in the 5-domain scale (n¼26),
stochastic imputation was used. A participant payment of either
£1 or £2 per session (based on the ﬁndings from our willingness-
to-pay analysis) was included in the sensitivity analysis, with
a mean attendance of 2 sessions per week for the full 16-week
programme at either £32 or £64. Economic subgroup analysis
was conducted for reason of referral, age group, gender and
adherence.30 Cost-effectiveness analysis was conducted using
Stata SE version 10. A nonparametric ManneWhitney U test
was used to compare HR-QoL due to the skewedness of the EQ-
5D data.
RESULTS
Participant flow and follow-up
Figure 1 shows participant ﬂow through the study and numbers
available for analysis; 1479 (68.5%) for 7D-PAR, 1795 (83.1%)
for imputed 7D-PAR and 992 (45.9%) for HADS. Response rates
were similar in the two groups. Of those allocated to the
intervention, 43.8% (n¼473) completed the 16-week
programme, 41.3% (n¼446) started the programme but did not
complete it and 14.9% (n¼161) failed to attend. Table 2 shows
baseline characteristics for those completing 7D-PAR (n¼1479)
and HADS measures (n¼992) at 12-month follow-up. Although
there is some evidence of greater loss to follow-up among
younger participants and those referred in whole or part for
mental health reasons, there was no strong evidence of differ-
ential loss to follow-up in terms of gender or deprivation.
Baseline data
Participants were aged between 16 and 88 years (mean 52, SD
14.7), predominately women (66%) and the vast majority
classed themselves as white (96%). Table 2 shows participants
were most likely to be referred for CHD risk factors only (72%)
or in combination with mental health issues (24%) and classed
themselves as inactive (58.6%) or moderately inactive (15.3%),
with 24% deﬁning themselves as either active or moderately
active. The economic analysis was based on 55% (n¼798) of the
participants in the effectiveness analysis. The economic sample
contained fewer younger participants (n¼140, 18%) than the
main trial (n¼1423, 30%), and included a higher proportion of
participants who were referred for CHD risk factors only
(n¼616, 77%) compared with the main sample (n¼1559, 71%).
More of them also completed the 16-week programme (62%,
n¼247), with fewer partial (32%, n¼123) and non-attenders
(8%, n¼30). The intervention and control groups were similar
for all baseline characteristics.
Table 2 Comparison of demographic characteristics by trial arm at baseline and for EuroQold5 Dimensions (EQ5D) and 12-month outcomes
Baseline EQ5D 7-D PAR HADS
Intervention Control Intervention Control Intervention Control Intervention Control
% (N) % (N) % (N) % (N) % (N) % (N) % (N) % (N)
Reasons for referral
CHD only 71.3 (770) 73.1 (789) 76.8 (307) 77.6 (309) 74 (536) 75.8 (572) 75.2 (360) 76.6 (393)
Mental health only 3.8 (41) 3.5 (38) 3.3 (13) 3.3 (13) 3.5 (25) 3.1 (23) 2.9 (14) 2.9 (15)
CHD and mental health 24.9 (269) 23.4 (253) 20.0 (80) 19.1 (976) 22.5 (163) 21.2 (160) 21.9 (105) 20.5 (105)
Age group
16e44 29.9 (322) 30.1 (323) 17.3 (69) 17.8 (71) 26.6 (192) 26.0 (196) 18.8 (90) 19.5 (100)
45e59 34.5 (371) 32.7 (352) 33.8 (135) 34.0 (136) 35.3 (255) 34.3 (258) 34.7 (166) 35.1 (180)
60+ 35.6 (383) 37.2 (400) 49.0 (196) 48.0 (191) 38.1 (275) 39.7 (299) 46.4 (222) 45.4 (233)
Gender
Male 34.4 (372) 34.5 (373) 33.8 (135) 32.7 (130) 34.5 (250) 33.3 (251) 35.1 (168) 33.1 (170)
Female 65.6 (708) 65.5 (707) 66.3 (265) 67.0 (268) 65.5 (474) 66.7 (504) 64.9 (311) 66.9 (343)
Welsh index of multiple deprivation tertile
Low 34.4 (361) 32.3 (340) 35.0 (140) 32.2 (128) 37.1 (262) 33.5 (246) 37.5 (173) 32.9 (165)
Middle 34.1 (358) 32.5 (342) 33.5 (134) 38.0 (152) 32.4 (232) 35.0 (257) 34.3 (158) 37.3 (187)
High 31.4 (330) 35.2 (370) 27.8 (111) 27.9 (111) 30 (212) 31.6 (232) 28.2 (130) 29.7 (149)
General practice physical activity questionnaire
Inactive 59.2 (623) 60.6 (643) 56.3 (225) 60.8 (242) 58.2 (411) 61.4 (455) 59.0 (276) 60.5 (306)
Moderate inactive 16.1 (170) 15.1 (160) 14.8 (59) 13.6 (54) 15.6 (116) 15.3 (113) 14.3 (67) 14.0 (71)
Moderate active 17.2 (181) 15.2 (161) 17.8 (71) 14.6 (58) 19.3 (136) 14.8 (110) 17.5 (82) 15.2 (77)
Active 7.5 (79) 9.2 (97) 8.5 (34) 9.8 (39) 6.4 (49) 8.5 (63) 9.2 (43) 10.3 (52)
Missing (27) (19) 2.8 (11) 1.3 (5)
Employment
Employed 32.7 (346) 28.4 (300) 26.3 (105) 24.6 (98) 32.7 (232) 29.5 (218) 27.0 (131) 27.7 (139)
Retired 30 (318) 32.9 (348) 41.3 (165) 41.7 (166) 32.7 (232) 35.1 (259) 38.8 (183) 40.2 (202)
Housework 18.8 (199) 20.3 (214) 16.3 (65) 18.9 (75) 17.0 (121) 20.6 (152) 17.0 (80) 18.5 (93)
Other 18.5 (196) 18.5 (195) 16.3 (62) 13.1 (52) 17.6 (125) 14.8 (109) 16.5 (78) 13.6 (68)
Missing 1.9 (21) 2.1 (23) 0.8 (3) 2.0 (8)
Education
Beyond min school leaving age 52.1 (557) 53.0 (570) 57.0 (228) 58 (231) 51.5 (370) 54.6 (410) 58.7 (280) 55.5 (284)
Total (n) 1080 1080 400 398 724 755 479 513
CHD, coronary heart disease; 7-D PAR, 7-day physical activity recall.
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Intervention effects
Table 3 presents the 12-month median scores and inter-quartile
range for the 7-D PAR and means and CIs for depression and
anxiety scores by trial arm and age, gender, Welsh Index of
Multiple Deprivation, adherence, reason for referral and baseline
GPPAQ. Table 4 shows the results of the regression analyses for
each of the primary outcomes at 12-month follow-up. For all
participants, those in the intervention group had higher levels of
physical activity than those in the control, but this was of
borderline statistical signiﬁcance. Among those referred for CHD
risk factors, the intervention group reported signiﬁcantly higher
levels of activity, but there was no difference among those
referred wholly or partially for mental health reasons. Among
this group of referrals, those randomised to NERS had signiﬁ-
cantly lower levels of both depression and anxiety.
Subgroup analyses showed effectiveness was highly depen-
dent on adherence, with signiﬁcantly greater differences in all
outcomes among those who completed the 16-week programme
compared with those who attended only partially or not at all.
There were also signiﬁcant interactions with gender for both
mental health outcomes, with the beneﬁcial effect of the inter-
vention only apparent among women. There was a suggestion
that the intervention was more effective on mental health
outcomes among the youngest age group (18e44), although this
was not statistically signiﬁcant. Effects did not vary signiﬁcantly
by deprivation status.
Cost effectiveness
The data on health-related quality of life and adherence to the
programme are summarised in table 5. A signiﬁcant difference
in HR-QoL between the intervention and control groups was
found using EQ-5D-VAS. For participants <44 years of age, the
difference between both EQ-5D and VAS scores was signiﬁ-
cant. 62% (n¼247) of the sample upon which economic anal-
ysis was undertaken completed the 16-week programme, 32%
(n¼123) attended fewer than 16 weeks and 8% (n¼30) did not
attend at all. There were no signiﬁcant differences in NHS
resource use between the intervention and control groups,
except that the control groups were referred for signiﬁcantly
more health-related tests (p¼<0.05) (data not presented). In
the base-case analysis, the difference in costs between inter-
vention and control group was £327, and the difference in
QALYs was 0.027, which generated an ICER point estimate of
£12 111 per QALY gained. The probability of the intervention
being cost effective was 89% at the NICE threshold of £30 000
per QALY.
The results of sensitivity and subgroup analyses are
summarised in table 6. Using the mean intervention and control
group 6-month EQ-5D score as an estimate for the baseline,
QALYs resulted in a decrease of the ICER from £12 111 (base
case) to £6055 per QALY. When only the control group’s mean
EQ-5D value at 6 months was used as an estimate of baseline
QALYs for both control and intervention groups, the ICER point
estimate was £7109. This analysis demonstrates that using the
6-month EQ-5D data as an estimate of baseline, QALYs in the
base-case analysis was a rather conservative approach. When
possible, participant payments of £1 and £2 per session were
added to the base-case analysis, the cost per QALY fell to £10 926
and £9741, respectively. Subgroup analyses found that the
intervention is likely to be more cost effective in: participants
with CHD and/or mental health risk factors compared with
participants with a risk of CHD only; female rather than male
participants; younger (<44 years) rather than older individuals.
Subgroup analysis based on those who had adhered fully to the Ta
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16-week programme indicated a saving of e£367 per QALY
gained.
DISCUSSION
Among those referred for CHD risk factors only, the NERS in
Wales was associated with signiﬁcantly higher levels of physical
activity when compared with normal care. However, among
those referred for mental health reasons, either solely or in
combination with CHD, there was no difference in physical
activity between the NERS and normal care participants at 12-
month follow-up. The primary analysis of the trial was of the
impact of the scheme on all referrals, and this was of borderline
statistical signiﬁcance, being in effect a pooled estimate of two
heterogeneous subgroup effects. Two recent systematic
reviews31 32 have highlighted the need to examine variation in
effectiveness based on medical condition, a view strongly
supported by the current study.
For patients referred for mental health reasons, the scheme
was not effective in helping them to increase physical activity.
Further planned analyses of data collected at 6 months will
allow an assessment of whether the scheme was effective in
increasing self-efﬁcacy and motivation to exercise among these
patients. Consistent with recent systematic review ﬁndings,31 32
patients referred for mental health reasons did appear to beneﬁt
in terms of reduced anxiety and depression, particularly in this
trial among women and younger patients. This suggests that for
these patients, the EP’s attention and the social contact and
support generated by scheme attendance may be the beneﬁcial
mechanisms rather than increased physical activity per se,
a hypothesis requiring further research.
One of the recent reviews also highlights the importance of
scheme uptake, adherence and their predictors in explaining
outcomes: NERS uptake at 85% was slightly above the average
(80%) found in the review.32 Although only 44% of intervention
participants adhered to the scheme throughout, this compares
favourably with the pooled rate of 37% across schemes assessed
by trials in the review.32 The relationship between adherence,
psychosocial processes and 12-month outcomes will be assessed
in future papers.
A pre-study review suggested that low-contact and low-
intensity physical activity interventions are more cost effective
than more intensive interventions.10 NERS is an intensive 16-
week programme which we have found to be likely to be cost
effective at conventional thresholds, a ﬁnding consistent with
recent cost-effectiveness reviews,32 33 which modelled lifetime
beneﬁts and showed a 51% probability of cost effectiveness at
£20 000 per QALY and 88% at £30 000 per QALY.
Strengths and weaknesses of the study
A pre-study systematic review of ERS found only six RCTs in
the UK and identiﬁed a number of shortcomings, including
Table 4 Main effects and interaction effects - ORs and 95% CIs from ordinal logistic regression models examining impacts of NERS on physical
activity and B coefficients and 95% CIs from linear regression models examining impacts of NERS on depression and anxiety
Effect Group 7-D PAR
7-D PAR plus
imputed values HADS depression HADS anxiety
Main effects Whole sample
All covariates included (n¼1443/1749/959/956)y 1.19 (0.99, 1.43) 1.18 (0.99, 1.42) 0.71* (1.25, 0.17) 0.54 (1.12, 0.35)
Baseline GPPAQ omitted (n¼1475/1788/976/973)y 1.20* (1.00, 1.45) 1.19* (1.00, 1.42) 0.74* (1.28, 0.20) 0.49 (1.06, 0.08)
CHD only
All covariates included (n¼1081/1302/732/729)y 1.29* (1.04, 1.60) 1.26* (1.02, 1.57) 0.60* (1.18, 0.02) 0.32 (0.95, 0.31)
Baseline GPPAQ omitted (n¼1105/1329/743/740)y 1.35** (1.09, 1.67) 1.30* (1.05, 1.60) 0.64* (1.22, 0.03) 0.27 (0.90, 0.35)
MH only or MH and CHD
Interaction effects All covariates included (n¼362/447/227/227)y 1.06 (0.73, 1.55) 1.04 (0.72, 1.52) 1.39* (2.60, 0.18) 1.56* (2.75, 0.38)
Baseline GPPAQ omitted (n¼370/459/233/233)y 0.94 (0.65, 1.36) 1.00 (0.69, 1.36) 1.32* (2.54, 0.10) 1.52* (2.68, 0.37)
Deprivation (n¼1405/1698/929/926)y
Medium x intervention 1.08 (0.69 to 1.70) 0.98 (0.63 to 1.55) 0.80 (0.50 to 2.09) 0.24 (1.64 to 1.15)
High x intervention 0.83 (0.52 to 1.32) 0.80 (0.52 to 1.25) 0.13 (1.50 to 1.25) 0.46 (1.94 to 1.02)
Adherence level (n¼1443/1749/959/956)y
Partial 1.00 (0.78 to 1.29) 1.00 (0.79 to 1.27) 0.12 (0.90 to 0.65) 0.12 (0.84 to 0.82)
Full 1.46* (1.17 to 1.84) 1.40* (1.11 to 1.79) 1.24* (1.88 to e0.61) 1.12* (1.80 to e0.44)
Gender (n¼1443/1749/959/956)y
Male x intervention 0.75 (0.51 to 1.10) 0.74 (0.51 to 1.07) 2.10* (0.98 to 3.23) 1.93* (0.72 to 3.14)
Age (n¼1443/1749/959/956)y
45e59 x intervention 1.36 (0.84 to 2.21) 1.36 (0.84 to 2.18) 0.61 (0.94 to 2.16) 2.03* (0.37 to 3.69)
60+ x intervention 0.99 (0.63 to 1.58) 1.04 (0.67 to 1.62) 0.65 (0.83 to 2.13) 1.07 (0.52 to 2.66)
*p<0.05; **p<0.01.
yn represents number of patients in 7-day PAR analyses/7-day PAR plus imputed values/HADS depression/HADS anxiety. All models include gender, LHB area, age group as covariates. Except
where stated, all models also include baseline GPPAQ as a further covariate.
CHD, coronary heart disease; GPPAQ, general practice physical activity questionnaire; HADS, Hospital Anxiety and Depression Scale; MH, mental health; 7-D PAR, 7-day physical activity recall.
Table 5 Mean cost-effectiveness outcomes by group over 12 months
Outcomes at 12 month
follow-up
Intervention
group mean (SD)
Control group
mean (SD) *p value
EQ-5D score (0e1)
Entire sample 0.64 (0.32) n¼395 0.61 (0.32) n¼391 0.09
<44 years 0.68 (0.33) n¼69 0.54 (0.34) n¼71 0.012*
45e60 years 0.58 (0.35) n¼132 0.59 (0.35) n¼131 0.88
>60 years 0.67 (0.28) n¼194 0.65 (0.27) n¼89 0.37
EQ-5D VAS (0e100)
Entire sample 68.8 (18.6) n¼397 63.9 (20) n¼394 0.0007*
<44 years 67.62 (19.1) n¼69 58.3 (20.2) n¼71 0.003*
45e60 years 66.1 (18.6) n¼135 62.0 (19.5) n¼133 0.13
>60 years 71.1 (18.2) n¼193 67.3 (19.8) n¼190 0.07
Adherence
Did not attend 30 (8%) NA NA
Attended <16 weeks 123 (32%) NA NA
Attended 16 weeks 247 (62%) NA NA
*Significant (p<0.05) according to ManneWhitney test.
EQ5D, EuroQold5 Dimensions; VAS, visual analogue scale.
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blinding of outcome measurement, the need for long-term
follow-up and the generalisability of the study population.5 A
more recent review of eight European RCTs31 suggested that
substantial heterogeneity in the quality and nature of schemes
may have contributed to inconsistent evidence of their effec-
tiveness and identiﬁed the need for further high-quality RCTs of
theoretically informed approaches to behaviour change
(including motivational interviewing). They also highlighted the
need to assess subgroup effectiveness.
In NERS, motivational interviewing was used as a clearly
identiﬁed approach to behaviour change, though implementa-
tion checks indicated that it was often poorly delivered16 with
data indicating that in practice, the key active ingredients of the
programme were the professionals’ support and supervision and
interaction with other patients.34 This suggests that scheme
effectiveness could be improved with increased attention to
ﬁdelity of motivational interviewing. The importance of
subgroup analysis based on medical condition is highlighted in
the inconsistent outcomes for CHD and mental health referrals
observed in the current study. In addition, the primary outcome
was collected at 12 months by researchers blinded to condition.
Physiological outcomes and objective measures of physical
activity were not collected. However, the 7D-PAR is well vali-
dated and was administered by telephone which provides a more
reliable measure than postal questionnaires.35 Conﬁdence in the
robustness of ﬁndings is enhanced by the relatively high
response rate achieved for the primary outcome (68.5%)
compared with equivalent community trials of ERS.5 Using
other measures of physical activity (Baecke and GPPAQ) to
impute scores for weekly activity for those without a 7D PAR
measure provided an enhanced response rate of 83.1%, although
it should be acknowledged that GPPAQ was developed as
a clinical screening, rather than a data-capture tool.
Signiﬁcantly, as a pragmatic policy evaluation, results are
likely to have high external validity and generalisabilty.36 There
was minimal control over the implementation of the interven-
tion, other than randomisation, and it was delivered across
Wales by a wide range of professionals to patients from areas
covering the full spectrum of socioeconomic circumstances. The
NERS in Wales shares many features of similar schemes imple-
mented across the UK.37
It should also be noted that there was a much lower response
rate to the 12-month postal questionnaire, and thus the
economic and mental health analyses are based on a smaller
number of participants. Although there was no strong
patterning in response rates, these may be subject to unmea-
sured response bias, and it is acknowledged that cost effective-
ness is assessed at 12 months only.
As in previous studies,5e7 it should be noted that a signiﬁcant
minority of trial participants, who were referred on the basis of
their clinician identifying them as sedentary, reported activity
levels at baseline which classed them as active or moderately
active by GPPAQ criteria. The inclusion of this subgroup may
What is already known on this subject
< Previous evaluations of Exercise Referral Schemess in the UK
have found only modest improvements in physical activity in
the short term, and there is uncertainty whether such
approaches are cost effective. These effects are partly
explained by poor rates of uptake and adherence to the
schemes and a lack of intervention relapse-prevention
strategies.
Table 6 Cost-effectiveness sensitivity (A) and subgroup analysis (B)
Intervention group (n) Control group (n)
Cost of
intervention (£) ICER (£)
Bootstrapped one-sided
95% CI for ICER (£)
Probability that intervention
is cost effective*
(A) Sensitivity analyses
Base case 395 391 385 12 111 58 881 89%
Mean intervention and control EQ-5D at
6 months as estimate of baseline
395 391 385 6055 37 159 96%
Control group mean EQ-5D value at
6 months as estimate of baseline
395 391 385 7109 24 853 98%
Participant payment of £1 per session 395 391 385e32¼353 10 926 69 085 91%
Participant payment of £2 per session 395 391 385e64¼321 9741 64 638 92%
Intervention group (n) Control group (n)
Incremental cost
(bootstrapped 95%CI)
Incremental QALY
(bootstrapped 95%CI)
ICER (bootstrapped
one-sided 95%CI)
(B) Subgroup analysis
Referral reason
CHD only 307 309 £239 (51 to 547) 0.0183 (50.0047 to 0.0416) £13 060 (117 893)
Mental health (MH) and MH plus CHD 80 76 £596 (5304 to 1616) 0.058 (0.017 to 0.100) £10 276 (50 925)
Gender
Male 135 130 £322 (5180 to 792) 0.0084 (e0.0250 to 0.0400) £38 333 (254 973)
Female 265 268 £326 (589 to 761) 0.0362 (0.0111 to 0.0623) £9006 (390 00)
Age
<44 years 69 71 £68 (5462 to 678) 0.0656 (0.0137 to 0.1148) £1037 (16 418)
44e60 years 135 136 £577 (5176 to 1373) 0.0179 (0.0194 to 0.0561) £32 235 (314 108)
>60 years 196 191 £244 (5131 to 586) 0.0187 (0.0057 to 0.0424) £13 048 (153 565)
Adherence
0 weeks 30 £1785 (25 to 4570) 0.0114 (0.0680 to 0.0390) NA
<16 weeks 123 £662 (212 to 1157) 0.0084 (0.0384 to 0.0218) NA
16 weeks 247 e£18 (5310 to 277) 0.049 (0.0277 to 0.0706) £367 (7068)
*At the £30 000 per QALY threshold.
EQ5D, EuroQold5 Dimensions; ICER, incremental cost-effectiveness ratio; QUALY, quality adjusted life year.
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well have contributed to higher levels of adherence and activity,
however, as a pragmatic policy trial it was important that these
individuals were not excluded. Given the number of policy and
practice constraints that have inhibited such evaluations,11 the
current study provides a relatively rare example of a pragmatic
randomised trial of a national ERS and demonstrates the feasi-
bility of calls for an increase in such trials of public health
interventions.38
CONCLUSION
NERS was effective in increasing physical activity among those
referred with CHD risk factors. Although there was no increase
in physical activity among those referred for mental health
reasons, anxiety and depression were reduced. These effects were
highly dependent on adherence to the programme. NERS is
likely to be cost effective under prevailing payer thresholds.
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